View in EDS

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.

Saved in:
Bibliographic Details
Title: Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Authors: Goldberg, Sarah B1 (AUTHOR) sarah.goldberg@yale.edu, Schalper, Kurt A2 (AUTHOR), Gettinger, Scott N1 (AUTHOR), Mahajan, Amit3 (AUTHOR), Herbst, Roy S1 (AUTHOR), Chiang, Anne C1 (AUTHOR), Lilenbaum, Rogerio1 (AUTHOR), Wilson, Frederick H1 (AUTHOR), Omay, Sacit Bulent4 (AUTHOR), Yu, James B5 (AUTHOR), Jilaveanu, Lucia1 (AUTHOR), Tran, Thuy1 (AUTHOR), Pavlik, Kira1 (AUTHOR), Rowen, Elin1 (AUTHOR), Gerrish, Heather1 (AUTHOR), Komlo, Annette1 (AUTHOR), Gupta, Richa1 (AUTHOR), Wyatt, Hailey1 (AUTHOR), Ribeiro, Matthew1 (AUTHOR), Kluger, Yuval2 (AUTHOR)
Source: Lancet Oncology. May2020, Vol. 21 Issue 5, p655-663. 9p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(20)30111-X